GlassScriptPhysician profile
Anna Suozzi Land
NPI 1366887929
$7,159.86
in general payments reported to CMS, 2019-2025
23 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.31 · 2020: $735 · 2021: $1,117 · 2022: $864 · 2023: $1,232 · 2024: $1,540 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,364.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,289.44 | 2020-2025 | Xeomin |
| Abbvie INC. | $919.33 | 2021-2025 | |
| Janssen Biotech, INC. | $784.38 | 2020-2025 | Tremfya |
| Galderma Laboratories, L.P. | $727.15 | 2020-2025 | Dysport, Aklief, Twyneo |
| Sun Pharmaceutical Industries INC. | $627.69 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Ucb, INC. | $601.87 | 2020-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $378.71 | 2019-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $362.23 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $246.13 | 2019-2025 | Jublia, Arazlo, Cabtreo |
| Novartis Pharmaceuticals Corporation | $217.16 | 2020-2025 | |
| Allergan, INC. | $198.21 | 2020-2022 | |
| Pfizer INC. | $193.06 | 2020-2025 | |
| Lilly USA, LLC | $114.45 | 2021-2025 | Taltz, Ebglyss |
| Genzyme Corporation | $106.00 | 2023-2024 | |
| Organon LLC | $72.36 | 2025 | Vtama |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $57.51 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $54.15 | 2020-2025 | |
| Amgen INC. | $47.24 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $45.44 | 2023-2024 | Opzelura |
| Lnhc, INC | $44.24 | 2025 | Zelsuvmi |
| Almirall LLC | $41.58 | 2022-2023 | Klisyri |
| Dermira, INC. | $19.03 | 2019 | |
| Prugen, INC. Pharmaceuticals | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Land listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.